Literature DB >> 4052975

Successful treatment of subacute cerebellar degeneration in ovarian carcinoma with plasmapheresis. A case report.

G Cocconi, G Ceci, G Juvarra, M R Minopoli, T Cocchi, F Fiaccadori, A Lechi, P Boni.   

Abstract

Subacute cerebellar degeneration is a rare complication of some neoplasms, and is generally resistant to therapy. A case of subacute cerebellar degeneration in a 50-year-old woman with a Stage II grade 3 serous ovarian adenocarcinoma is reported. The onset of the neurologic symptoms preceded the diagnosis of cancer and progressively worsened during and after four cycles of chemotherapy. A quick, partial improvement of the neurologic syndrome was documented after three weekly treatments with plasmapheresis. The contribution of circulating factors in inducing subacute cerebellar degeneration can be postulated. A trial using this new type of treatment should be performed in patients who have this therapeutically refractory clinical condition.

Entities:  

Mesh:

Year:  1985        PMID: 4052975     DOI: 10.1002/1097-0142(19851101)56:9<2318::aid-cncr2820560930>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  A review of the therapy of paraneoplastic neurologic syndromes.

Authors:  A Das; F H Hochberg; S McNelis
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Paraneoplastic Diseases of the Nervous System.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

3.  Progress in the management of paraneoplastic neurological disorders.

Authors:  Hamid Sadeghian; Steven Vernino
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

Review 4.  Neurological paraneoplastic syndromes.

Authors:  J Dalmau; J B Posner
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody.

Authors:  Surasak Phuphanich; Charles Brock
Journal:  J Neurooncol       Date:  2006-06-14       Impact factor: 4.130

6.  Immunomodulatory treatment trial for paraneoplastic neurological disorders.

Authors:  Steven Vernino; Brian Patrick O'Neill; Randolph S Marks; Judith R O'Fallon; David W Kimmel
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

7.  Purkinje cell antibodies in a patient with cerebellar disorder: detection of responsible antigenic proteins.

Authors:  J W Unger; P W Reisinger; D Huppert
Journal:  J Neurol       Date:  1991-08       Impact factor: 4.849

Review 8.  Paraneoplastic syndromes in small cell lung cancer.

Authors:  Zaid Soomro; Michael Youssef; Shlomit Yust-Katz; Ali Jalali; Akash J Patel; Jacob Mandel
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 3.005

9.  Paraneoplastic syndromes in patients with ovarian neoplasia.

Authors:  C N Hudson; M Curling; P Potsides; D G Lowe
Journal:  J R Soc Med       Date:  1993-04       Impact factor: 18.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.